Unlike the glucagon injections, BAQSIMI™ is ready to use. It offers an easier way to treat a severe hypoglycemia in people living with diabetes treated with insulin. A severe hypoglycemia occurs when those people cannot treat themselves.
BAQSIMI™ is indicated in adults and children of at least 4 years old treated with insulin. The dose does not need to be inhaled so it is effective even if a person has a cold.
A dose of 3 mg costs about 130 $ and is not covered by Quebec’s basic prescription drug insurance plan for now.
People living with diabetes treated with insulin can get BAQSIMI™ with or without a prescription.
Consult the product’s monograph here !
References :
BAQSIMI (product monograph). Toronto, ON: Eli Lilly Canada Inc .: 2019.
Type 1-Better (2019). Glucagon nasal : désormais disponible au Québec ! (French only) [Online] https://type1better.com/fr/glucagon-nasal-desormais-disponible-au-quebec (page consulted on November 28th, 2019).
Eli Lilly Canada Inc (2019). Baqsimi. [Online] https://www.baqsimi.com/ (page consulted on November 29th, 2019).